8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      High-Performance Self-Cascade Pyrite Nanozymes for Apoptosis-Ferroptosis Synergistic Tumor Therapy.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          As next-generation artificial enzymes, nanozymes have shown great promise for tumor catalytic therapy. In particular, their peroxidase-like activity has been employed to catalyze hydrogen peroxide (H2O2) to produce highly toxic hydroxyl radicals (•OH) to kill tumor cells. However, limited by the low affinity between nanozymes with H2O2 and the low level of H2O2 in the tumor microenvironment, peroxidase nanozymes usually produced insufficient •OH to kill tumor cells for therapeutic purposes. Herein, we present a pyrite peroxidase nanozyme with ultrahigh H2O2 affinity, resulting in a 4144- and 3086-fold increase of catalytic activity compared with that of classical Fe3O4 nanozyme and natural horseradish peroxidase, respectively. We found that the pyrite nanozyme also possesses intrinsic glutathione oxidase-like activity, which catalyzes the oxidation of reduced glutathione accompanied by H2O2 generation. Thus, the dual-activity pyrite nanozyme constitutes a self-cascade platform to generate abundant •OH and deplete reduced glutathione, which induces apoptosis as well as ferroptosis of tumor cells. Consequently, it killed apoptosis-resistant tumor cells harboring KRAS mutation by inducing ferroptosis. The pyrite nanozyme also exhibited favorable tumor-specific cytotoxicity and biodegradability to ensure its biosafety. These results indicate that the high-performance pyrite nanozyme is an effective therapeutic reagent and may aid the development of nanozyme-based tumor catalytic therapy.

          Related collections

          Author and article information

          Journal
          ACS Nano
          ACS nano
          American Chemical Society (ACS)
          1936-086X
          1936-0851
          March 23 2021
          : 15
          : 3
          Affiliations
          [1 ] CAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
          [2 ] School of Future Technology, University of Chinese Academy of Sciences, Beijing 101408, China.
          [3 ] Department of Pharmacology, School of Medicine, Institute of Translational Medicine, Yangzhou University, Yangzhou 225001, Jiangsu, China.
          [4 ] School of Life Sciences, Tsinghua University, Beijing 100084, China.
          [5 ] Laboratory of Theoretical and Computational Nanoscience, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing 100190, China.
          [6 ] Suzhou Institute of Systems Medicine, Center for Systems Medicine, Chinese Academy of Medicine Sciences, Suzhou 215123, Jiangsu, China.
          [7 ] Nanozyme Medical Center, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450052, Henan, China.
          [8 ] Department of Otolaryngology and Institute of Translational Medicine, Shenzhen Second People's Hospital/The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen 518035, Guangdong, China.
          Article
          10.1021/acsnano.1c01248
          33705663
          423a0b88-5ca0-43f6-9f65-3666f6b16155
          History

          apoptosis−ferroptosis synergistic tumor therapy,glutathione oxidase-like activity,peroxidase-like activity,pyrite nanozyme,self-cascade,tumor catalytic therapy

          Comments

          Comment on this article